Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$4.36	$4.30	$1.78 ▼ $5.75	$96.26M	0.87	452,470 shs	N/A
ATRA Atara Biotherapeutics	$8.39 -3.8%	$10.00	$3.92 ▼ $19.15	$75.60M	0.08	75,210 shs	81,341 shs
CLLS Cellectis	$2.63 -1.5%	$3.24	$1.77 ▼ $5.48	$263.89M	2.88	20,548 shs	8,005 shs
INBX Inhibrx Biosciences	$87.39 -1.9%	$98.37	$20.55 ▼ $155.29	$1.28B	3.41	327,934 shs	272,117 shs
KRYS Krystal Biotech	$354.86 +3.8%	$331.38	$130.50 ▼ $382.54	$10.46B	0.5	333,429 shs	683,068 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	0.00%	0.00%	0.00%	0.00%	+57.97%
ATRA Atara Biotherapeutics	0.00%	-14.04%	-16.68%	+59.20%	-9.59%
CLLS Cellectis	0.00%	-12.04%	-11.74%	-40.50%	+32.16%
INBX Inhibrx Biosciences	0.00%	-6.04%	-6.08%	-0.95%	+269.51%
KRYS Krystal Biotech	0.00%	-2.99%	+1.95%	+29.41%	+136.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$4.36	$4.30	$1.78 ▼ $5.75	$96.26M	0.87	452,470 shs	N/A
ATRA Atara Biotherapeutics	$8.39 -3.8%	$10.00	$3.92 ▼ $19.15	$75.60M	0.08	75,210 shs	81,341 shs
CLLS Cellectis	$2.63 -1.5%	$3.24	$1.77 ▼ $5.48	$263.89M	2.88	20,548 shs	8,005 shs
INBX Inhibrx Biosciences	$87.39 -1.9%	$98.37	$20.55 ▼ $155.29	$1.28B	3.41	327,934 shs	272,117 shs
KRYS Krystal Biotech	$354.86 +3.8%	$331.38	$130.50 ▼ $382.54	$10.46B	0.5	333,429 shs	683,068 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	0.00%	0.00%	0.00%	0.00%	+57.97%
ATRA Atara Biotherapeutics	0.00%	-14.04%	-16.68%	+59.20%	-9.59%
CLLS Cellectis	0.00%	-12.04%	-11.74%	-40.50%	+32.16%
INBX Inhibrx Biosciences	0.00%	-6.04%	-6.08%	-0.95%	+269.51%
KRYS Krystal Biotech	0.00%	-2.99%	+1.95%	+29.41%	+136.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	1.80	Reduce	$10.50	140.83% Upside
ATRA Atara Biotherapeutics	2.00	Hold	$9.50	13.23% Upside
CLLS Cellectis	2.83	Moderate Buy	$7.00	166.16% Upside
INBX Inhibrx Biosciences	2.33	Hold	$150.00	71.64% Upside
KRYS Krystal Biotech	2.83	Moderate Buy	$360.67	1.64% Upside

Current Analyst Ratings Breakdown

Latest KRYS, CLLS, INBX, ATRA, and ADVM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	KRYS Krystal Biotech	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$364.00 ➝ $396.00
7/13/2026	KRYS Krystal Biotech	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$474.00
7/1/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
6/18/2026	KRYS Krystal Biotech	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$306.00 ➝ $403.00
6/16/2026	INBX Inhibrx Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/16/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
6/16/2026	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$310.00 ➝ $361.00
6/11/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
6/1/2026	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$310.00
5/28/2026	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$9.00

(Data available from 7/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	$3.40 per share	N/A
ATRA Atara Biotherapeutics	$120.77M	0.63	$4.85 per share	1.73	($5.34) per share	-1.57
CLLS Cellectis	$79.59M	3.32	N/A	N/A	$0.76 per share	3.46
INBX Inhibrx Biosciences	$1.30M	986.23	N/A	N/A	$0.55 per share	158.89
KRYS Krystal Biotech	$389.13M	26.88	$7.29 per share	48.68	$42.06 per share	8.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$8.58	N/A	N/A	N/A	N/A	-3,476.17%	-152.07%	N/A
ATRA Atara Biotherapeutics	$32.69M	-$0.67	N/A	5.99	N/A	-40.91%	-79.12%	-35.29%	8/10/2026 (Estimated)
CLLS Cellectis	-$67.59M	-$0.67	N/A	N/A	N/A	-89.51%	-80.66%	-20.51%	7/30/2026 (Estimated)
INBX Inhibrx Biosciences	-$140.05M	-$8.39	N/A	N/A	N/A	N/A	-563.90%	-72.32%	8/12/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.48	47.44	37.24	N/A	53.92%	19.25%	17.62%	8/3/2026 (Estimated)

Latest KRYS, CLLS, INBX, ATRA, and ADVM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	INBX Inhibrx Biosciences	-$2.28	N/A	N/A	N/A	N/A	N/A
8/11/2026	H1 2026	CLLS Cellectis	-$0.2630	N/A	N/A	N/A	$11.05 million	N/A
8/10/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	N/A	N/A	N/A	$0.55 million	N/A
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.70	N/A	N/A	N/A	$122.61 million	N/A
5/14/2026	Q1 2026	INBX Inhibrx Biosciences	-$1.6750	-$2.15	-$0.4750	-$2.15	N/A	N/A
5/12/2026	Q1 2026	ATRA Atara Biotherapeutics	-$0.3295	-$0.29	+$0.0395	-$0.29	$2.90 million	$0.52 million
5/11/2026	Q1 2026	CLLS Cellectis	-$0.2583	-$0.18	+$0.0783	-$0.18	$11.04 million	$7.55 million
5/4/2026	Q1 2026	KRYS Krystal Biotech	$1.45	$1.83	+$0.38	$1.83	$112.11 million	$116.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	0.65	0.65
ATRA Atara Biotherapeutics	N/A	2.16	2.16
CLLS Cellectis	1.13	1.52	1.52
INBX Inhibrx Biosciences	12.58	6.46	6.46
KRYS Krystal Biotech	N/A	9.46	9.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
ATRA Atara Biotherapeutics	70.90%
CLLS Cellectis	63.90%
INBX Inhibrx Biosciences	82.46%
KRYS Krystal Biotech	86.29%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
ATRA Atara Biotherapeutics	41.20%
CLLS Cellectis	16.41%
INBX Inhibrx Biosciences	18.26%
KRYS Krystal Biotech	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	22.08 million	20.75 million	Optionable
ATRA Atara Biotherapeutics	330	9.01 million	5.30 million	No Data
CLLS Cellectis	290	100.34 million	83.87 million	Optionable
INBX Inhibrx Biosciences	166	14.67 million	11.99 million	Optionable
KRYS Krystal Biotech	210	29.48 million	25.62 million	Optionable

KRYS, CLLS, INBX, ATRA, and ADVM Headlines

Recent News About These Companies

Principal Financial Group Inc. Decreases Stake in Krystal Biotech, Inc. $KRYS

July 19 at 4:47 AM | marketbeat.com

Hanseatic Management Services Inc. Buys Shares of 2,997 Krystal Biotech, Inc. $KRYS

July 19 at 4:31 AM | marketbeat.com

Krystal Biotech, Inc. $KRYS Shares Sold by C WorldWide Group Holding A S

July 17 at 4:31 AM | marketbeat.com

Krystal Biotech (NASDAQ:KRYS) Shares Down 6.4% - Time to Sell?

July 14, 2026 | marketbeat.com

Bank of America Raises Krystal Biotech (NASDAQ:KRYS) Price Target to $396.00

July 14, 2026 | marketbeat.com

Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Rating of "Moderate Buy" from Analysts

July 5, 2026 | marketbeat.com

SG Americas Securities LLC Has $1.52 Million Stake in Krystal Biotech, Inc. $KRYS

July 3, 2026 | marketbeat.com

Krystal Biotech, Inc. $KRYS Stake Decreased by Pictet Asset Management Holding SA

July 2, 2026 | marketbeat.com

Krystal Biotech (NASDAQ:KRYS) Reaches New 52-Week High - Time to Buy?

July 1, 2026 | marketbeat.com

Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?

June 29, 2026 | zacks.com

Louisiana State Employees Retirement System Purchases Shares of 11,400 Krystal Biotech, Inc. $KRYS

June 29, 2026 | marketbeat.com

Krystal Biotech (NASDAQ:KRYS) EVP Sells 1,000 Shares

June 27, 2026 | insidertrades.com

Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI)

June 25, 2026 | finance.yahoo.com

The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream

June 24, 2026 | insidermonkey.com

The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream

June 24, 2026 | finance.yahoo.com

3 Biotech Firms With Major Potential Catalysts in the Coming Months (KRYS)

...

June 22, 2026 | marketbeat.com

Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now?

June 7, 2026 | insidermonkey.com

Insider Selling: Krystal Biotech (NASDAQ:KRYS) Insider Sells 25,000 Shares of Stock

June 6, 2026 | insidertrades.com

Is the Options Market Predicting a Spike in Krystal Biotech Stock?

June 5, 2026 | zacks.com

Krystal Biotech Stock Soars 16% in Three Months: Here's Why

June 4, 2026 | zacks.com

Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?

June 3, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KRYS, CLLS, INBX, ATRA, and ADVM Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Atara Biotherapeutics NASDAQ:ATRA

$8.39 -0.33 (-3.78%)

As of 07/17/2026 04:00 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Cellectis NASDAQ:CLLS

$2.63 -0.04 (-1.50%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$2.62 -0.01 (-0.38%)

As of 07/17/2026 07:13 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Inhibrx Biosciences NASDAQ:INBX

$87.39 -1.68 (-1.89%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$88.00 +0.61 (+0.70%)

As of 07/17/2026 04:10 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Krystal Biotech NASDAQ:KRYS

$354.86 +13.07 (+3.82%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$354.52 -0.34 (-0.10%)

As of 07/17/2026 07:57 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KRYS, CLLS, INBX, ATRA, and ADVM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KRYS, CLLS, INBX, ATRA, and ADVM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KRYS, CLLS, INBX, ATRA, and ADVM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KRYS, CLLS, INBX, ATRA, and ADVM Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

Atara Biotherapeutics NASDAQ:ATRA

Cellectis NASDAQ:CLLS

Inhibrx Biosciences NASDAQ:INBX

Krystal Biotech NASDAQ:KRYS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools